[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracerebral-hemorrhage-lobar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracerebral-hemorrhage-lobar":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,73,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053979","evacuation-of-lobar-intracranial-hemorrhage-using-microsurgical-technique-eliminate-100053979",false,"NCT07697742","Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE)","Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE): A Prospective Observational Surgical Cohort Study of Feasibility, Safety, and Radiographic Outcomes","ELIMINATE","Inclusion Criteria:\n\n* • Adults \\> 18 years\n\n  * CT evidence of acute, spontaneous lobar ICH defined as located \\\u003C1cm from the cortical surface\n  * ICH volume is \\>30cc but \\\u003C80cc as measured by (length x width x height)\u002F2\n  * GCS 5-14 at presentation\n  * NIHSS \\>5\n  * Surgery deemed to be feasible within 16h of symptom onset\n\nExclusion Criteria:\n\n* • Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)\n\n  * Intraventricular extension estimated to involve \\>50% of the lateral ventricle\n  * Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS\\>1 at baseline)\n  * Individuals presenting with GCS \\\u003C5 at presentation\n  * Primary basal ganglia hemorrhage with lobar extension\n  * End-stage organ failure or life expectancy \\\u003C6 months\n  * For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.","ALL","18 Years",{"count":20,"type":21},27,"ESTIMATED","OBSERVATIONAL","ELIMINATE is a cohort study, phase 2A, designed to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume \\\u003C15cc on 24-hour postoperative CT imaging.",[25],"Intracerebral Hemorrhage Lobar",[27,28],"intracerebral hemorrhage","lobar ICH","NOT_YET_RECRUITING","2026-07-08",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":21},"2026-09-01",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Dr. Michael D Hill","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":41},"100629175","phase-3-neuronavigation-assisted-stereotactic-minimally-invasive-puncture-with-tenecteplase-for-acute-lobar-intracerebral-hemorrhage-100629175","NCT07471256","Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage","Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined With Tenecteplase for the Treatment of Acute Spontaneous Lobar Intracerebral Hemorrhage(NALICE-TNK)： a Randomized, Outcome-blinded, Multi-center Trial","NALICE-TNK","Inclusion Criteria:\n\n1. Age ≥18 years and \\\u003C80 years\n2. Symptoms must have manifested within 24 hours prior to the diagnostic CT (dCT) scan. Patients with indeterminate symptom onset are excluded; for those who awoke with symptoms, the last known well time is used.\n3. Acute spontaneous lobar intracerebral hemorrhage (ICH) occurring in the frontal lobe, parietal lobe, temporal lobe, or occipital lobe, with a volume between 30-50 mL, measured at the site using the ABC\u002F2 method with radiographic imaging (CT, etc.).\n4. Glasgow Coma Scale (GCS) score of 5-14.\n5. Stability CT scan done at least 6 hours after diagnostic CT showing clot stability (growth\\\u003C5 mL as measured by ABC\u002F2 method).\n6. Randomization should occur within 6 to 24 hours after the diagnostic CT.\n7. Systolic blood pressure (SBP) less than 180 mmHg maintained for a duration of six hours, documented proximate to the randomization time point.\n8. Historical modified Rankin (mRS) score of 0 or 1.\n\nExclusion Criteria:\n\n1. Hemorrhage in the basal ganglia, thalamus, or subtentorial region, including posterior fossa and cerebellar hemorrhage.\n2. Stability CT scan done at least 6 hours after diagnostic CT showing clot instability (growth ≥5 mL as measured by ABC\u002F2 method).\n3. Intraventricular hemorrhage necessitating intervention to address mass effect or midline shift attributable to trapped ventricle syndrome secondary to intraventricular hemorrhage (IVH)-related casting.\n4. Hemorrhage attributable to other cerebrovascular pathologies, including but not limited to ruptured aneurysm, arteriovenous malformation (AVM), vascular anomalies, moyamoya disease, hemorrhagic transformation of an ischemic infarct, or recurrence of a recent hemorrhage within the past year, as diagnosed through radiographic imaging.\n5. Patients presenting with an unstable intracranial mass or progressive intracranial compartment syndrome.\n6. National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.\n7. Presence of puncture contraindications.\n8. Irreversible impairment of brainstem function, characterized by bilateral fixed and dilated pupils, extensor motor posturing, and a Glasgow Coma Scale (GCS) score of ≤ 4.\n9. Indications for craniotomy in patients include: 1) progressive impairment of consciousness; 2) presence of brain herniation, with signs related to cerebellar tonsil herniation or temporal lobe gyrus herniatio.\n10. CT evidence suggesting a high risk of rebleeding, such as spot sign.\n11. Platelet count \\\u003C100,000\u002FmL; INR \\>1.4.\n12. Any irreversible coagulation disorders (e.g., hemophilia, von Willebrand disease, use of anticoagulants such as warfarin) or known clotting disorders (e.g., hypercoagulable states).\n13. Inability to maintain INR ≤1.4 using short-acting and long-acting procoagulants (e.g., recombinant human coagulation factor VIIa, fresh frozen plasma, vitamin K, etc.).\n14. Subjects necessitating long-term anticoagulation therapy are excluded from participation. Reversal of anticoagulation is permissible for medically stable patients who can feasibly tolerate the short-term risks associated with reversal. Patients must not require coumadin (warfarin) or other anticoagulants during the initial 8-week period.\n15. Prior to the onset of symptoms, anticoagulants such as dabigatran, apixaban, or rivaroxaban, as well as treatments like tirofiban, ticagrelor, cilostazol, or clopidogrel, were used.\n16. Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary system, or respiratory tract bleeding.\n17. Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures, etc.) or site of recent surgical intervention.\n18. Positive urine or serum pregnancy test in pre-menopausal female subjects without a documented history of surgical sterilization.\n19. Allergy\u002Fsensitivity to TNK.\n20. Prior enrollment in the study.\n21. Engagement in a concurrent interventional clinical investigation or trial. Patients enrolled in observational, natural history, or epidemiological studies that do not involve any form of intervention remain eligible.\n22. Not expected to survive until the day 180 visit due to co-morbidities, or having DNR\u002FDNI status (Do-Not-Resuscitate and Do-Not-Intubate) prior to randomization.\n23. The presence of any concurrent serious illness that could confound outcome assessments, including but not limited to hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, or hematologic disorders.\n24. Patients with mechanical heart valves are excluded. The presence of bioprosthetic valve (s) is permissible.\n25. Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.\n26. Any other condition that, in the investigator's judgment, would present a significant risk to the subject if the investigational therapy were to be initiated.\n27. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n28. Patients deemed by the investigator to have unstable conditions that may benefit from other treatments.\n29. Patients requesting conservative treatment or standard craniotomy microsurgery treatment.\n30. The subject or their legal guardian\u002Frepresentative demonstrates an inability or lack of willingness to provide written informed consent.","80 Years",{"count":52,"type":21},636,"INTERVENTIONAL",[55],"PHASE3","Introduction: Minimally invasive puncture surgery with thrombolysis is effective for hypertensive intracerebral hemorrhage, but its effect on neurological recovery remains uncertain. The use of neuronavigation-assisted stereotactic technology can significantly improve the precision of catheter placement, while tenecteplase (TNK), a third-generation thrombolytic with high fibrin specificity and superior activity against platelet-rich clots. Nonetheless, the efficacy and safety of combining neuronavigation-assisted stereotactic minimally invasive puncture (NALCIE) with TNK for reducing disability and mortality in acute spontaneous lobar intracerebral hemorrhage have yet to be established.\n\nAim: To present the scientific rationale and study design of the neuronavigation-assisted stereotactic minimally invasive puncture combined with tenecteplase (NALICE-TNK) trial for the treatment of acute spontaneous lobar intracerebral hemorrhage.\n\nDesign: NALICE-TNK is a multicenter, randomized, open-label, assessor-blinded, clinical trial enrolling 636 patients with acute lobar intracerebral hemorrhage and hematoma volumes of 30-50 mL. The trial aims to assess the efficacy and safety of neuronavigation-assisted stereotactic minimally invasive puncture (MIPS) combined with tenecteplase (TNK), administered every 24 hours at a dose of 0.009 mg per mL of hematoma volume, versus standard medical care. All participants will undergo standardized 180-day follow-up.\n\nStudy outcomes: The primary efficacy endpoint is functional ambulation (a score of 0 to 3 on the modified Rankin scale; range, 0 to 6, with higher scores indicating more severe disability) at 180 days. The primary safety endpoint is all-cause mortality at 30 days.",[25],[59,60,61,62,63,64],"Neuronavigation-assisted Stereotactic","Lobar intracerebral hemorrhage","Minimally invasive puncture","Tenecteplase (TNK)","Multicenter randomized trial","Hematoma evacuation","2026-03-22",{"date":67,"type":33},"2026-03-25",{"date":69,"type":21},"2026-03-31",{"date":37,"type":21},{"name":72,"class":40},"Beijing Tiantan Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":53,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100595018","phase-2-colchicine-for-the-prevention-of-recurrence-in-cerebral-amyloid-angiopathy-related-intracerebral-hemorrhage-100595018","NCT07026994","Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage","Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage (CARE-ICH)","CARE-ICH","Inclusion Criteria:\n\n* Age ≥55 years;\n* Diagnosed with \"probable CAA with supporting pathology\" or \"probable CAA\" according to the modified Boston criteria (version 1.5);\n* High risk of recurrent ICH, defined as: 1 prior symptomatic ICH and presence of cortical superficial siderosis (cSS), or ≥2 prior symptomatic ICHs;\n* Time interval since symptom onset of the most recent ICH: ≤3 months (earlier enrollment is preferred if criteria are met);\n* Modified Rankin Scale (mRS) score ≤4 at randomization;\n* Written informed consent from the participant or their legally authorized representative before study enrollment.\n\nExclusion Criteria:\n\n* Secondary causes of ICH;\n* Pre-existing moderate-to-severe renal, liver or blood disorders (anaemia \\[hemoglobin \\\u003C10g\u002FdL\\], thrombocytopaenia \\[platelet count \\\u003C100×109\u002FL\\], leucopenia \\[white blood cell \\\u003C3×109\u002FL\\], cirrhosis or severe hepatic dysfunction, renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C15mL\u002Fmin\\]);\n* Prior diagnosis of gout, peripheral neuropathy, myopathy, inflammatory bowel disease or chronic diarrhea;\n* Concurrent treatment with regular immune-suppressant (corticosteroids, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab), moderate-to-strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir\u002Fritonavir, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir\u002Fritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine);\n* Known allergy, sensitivity or intolerance to colchicine;\n* Contraindications or inability to complete brain MRI or susceptibility weighted imaging (SWI) scans;\n* Pregnancy or breastfeeding;\n* Recent participation in any other interventional study in the past 30 days before enrollment;\n* Not expected to survive the follow-up period;\n* Inability to adhere to study procedures;\n* Any condition in which investigators believe that participating in this study may be harmful to the patient.","55 Years",{"count":83,"type":21},80,[85],"PHASE2","The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence.\n\nThe main questions it aims to answer are:\n\n* Is colchicine safe for CAA-ICH patients?\n* Is colchicine well tolerated for CAA-ICH patients? Researchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine is safe and tolerable for CAA-ICH patients and works to prevent ICH recurrence.\n\nParticipants will:\n\n* Take colchicine or a placebo every day for 12 months\n* Receive telephone follow-ups at 3 and 9 months, and visit the clinic at 6 and 12 months for checkups and tests\n* Control blood pressure and improve lifestyle",[88,25],"Cerebral Amyloid Angiopathy",[88,90,91,92],"Intracerebral Hemorrhage","Colchicine","Recurrence","RECRUITING","2025-06-22",{"date":96,"type":33},"2025-06-26",{"date":98,"type":33},"2025-06-18",{"date":100,"type":21},"2027-12",{"name":102,"class":40},"Huashan Hospital",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":112,"targetDuration":4,"studyType":53,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":41},"100586917","phase-4-neuroendoscopic-hematoma-evacuation-combined-with-methylprednisolone-sodium-succinate-in-the-treatment-of-lobar-intracerebral-hemorrhage-at-the-early-stage-100586917","NCT06921616","Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.","A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.","HEMS","Inclusion Criteria:\n\n1. The age ranges from 18 to 80 years old.\n2. Diagnosed as spontaneous intracerebral hemorrhage (ICH) by cranial computed tomography (CT) examination, with the bleeding site located in the lobar region of the brain.\n3. Calculate the hematoma volume according to the cranial CT examination, which should be within the range of 30 to 80 ml, and the shift of the midline structure at the level of the pineal gland is less than 3 mm. The formula for calculating the hematoma volume V (cubic centimeters) is V = A × B × C × 1\u002F2. Here, A represents the longest diameter (in centimeters) of the largest hematoma layer on the horizontal position of the plain CT scan, B refers to the widest diameter (in centimeters) of the hematoma perpendicular to A on this plane, and C stands for the thickness (in centimeters) of the hematoma shown on the CT film.\n4. The time interval from the onset of the disease to randomization is within 24 hours. In case the actual onset time is not clear, the onset time will be regarded as the time when the subject was last confirmed to be in good health.\n5. The National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 points at the time of randomization.\n6. The Glasgow Coma Scale (GCS) score is between 5 and 14 points at the time of randomization.\n7. The modified Rankin Scale (mRS) score is 0-1 points prior to the onset of the disease.\n8. The patient and his or her legal representative sign the written informed consent form.\n\nExclusion Criteria:\n\n1. Hemorrhage in other locations (e.g., hemorrhage in infratentorial sites such as the basal ganglia, thalamus, brainstem, or cerebellum).\n2. Hemorrhage due to other causes (e.g., hemorrhage resulting from aneurysm, arteriovenous malformation, brain trauma, brain tumor, hemorrhagic transformation of large-area cerebral infarction, hemorrhage caused by amyloid angiopathy, hemorrhage due to coagulation disorders) or complicated by aneurysm, arteriovenous malformation, brain trauma, brain tumor, large-area cerebral infarction, amyloid angiopathy, severe coagulation disorders.\n3. Patients with intraventricular hemorrhage or those in whom intracerebral hemorrhage (ICH) has ruptured into the ventricles and who are considered to require external ventricular drainage.\n4. A history of any parenchymal brain hemorrhage or other intracranial subarachnoid, subdural, or epidural hemorrhage and a history of relevant surgeries within the past 30 days.\n5. Patients with genetic or acquired bleeding tendencies, coagulation disorders such as deficiency of coagulation factors.\n6. Platelet count \\\u003C 75 × 10⁹\u002FL.\n7. Undergoing anticoagulant drug treatment with warfarin, dabigatran, or rivaroxaban, etc. within one week before enrollment, and having an international normalized ratio (INR) \\> 1.4.\n8. Expected to require long-term anticoagulation and antiplatelet therapy.\n9. A history of previous internal hemorrhage, with risks of gastrointestinal bleeding (such as gastrointestinal ulcers), genitourinary bleeding, or respiratory tract bleeding that has not been fully controlled.\n10. Myocardial infarction occurring within the past 30 days.\n11. Known to have a high embolism risk, including patients with mechanical heart valves implanted in vivo, a history of left heart thrombus, mitral stenosis accompanied by atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is eligible.\n12. Severe liver function impairment, with alanine aminotransferase (ALT) \\> 3 times the upper limit of the normal range, or aspartate aminotransferase (AST) \\> 3 times the upper limit of the normal range. Severe renal insufficiency, with a glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m².\n13. Patients with Alzheimer's disease or mental disorders who are unable to complete the follow-up plan as required.\n14. Complicated by any severe diseases that, upon evaluation, may interfere with the trial results, including diseases of the respiratory system, circulatory system, digestive system, genitourinary system, endocrine system, immune system, and hematopoietic system, etc.\n15. Allergic to drugs or devices related to the operation.\n16. Pregnant or lactating women, or those planning to become pregnant within one year.\n17. In the terminal stage of any disease with an expected lifespan of less than 6 months.\n18. Currently participating in other clinical trials or having been previously enrolled in this trial.\n19. The patient or his\u002Fher legal guardian is unwilling to sign the written informed consent form.",{"count":113,"type":21},396,[115],"PHASE4","The aim of this trial is to investigate whether neuroendoscopic hematoma evacuation combined with early use of methylprednisolone sodium succinate can improve the efficacy and safety in the treatment with that of simple neuroendoscopic surgery alone for patients with spontaneous lobar intracerebral hemorrhage within 24 hours after the onset.",[118,25,119,120],"Stroke","Methylprednisolone","Surgery","2025-04-10",{"date":123,"type":33},"2025-04-13",{"date":125,"type":21},"2025-05-01",{"date":127,"type":21},"2027-01-31",{"name":129,"class":40},"Yong Jiang"]